NMB Therapeutics


Developer and licensor of a nanoparticle-based nitric oxide delivery platform intended to enable controlled, sustained and tunable nitric-oxide (NO) bioavailability. The company partners with pharmaceutical and cosmeceutical firms to evaluate APIs, develop formulations and progress products from feasibility through preclinical evaluation and commercialization support across topical, inhalation, oral, IV and transmucosal routes.

Industries

biotechnology
life-science
pharmaceutical

NMB Therapeutics

Hempstead, New York, United States, North America


Products

Nitric-oxide releasing nanoparticle delivery platform

A nanoparticle-based delivery system that encapsulates nitric-oxide donors and other actives to provide controlled and sustained NO release across multiple routes (topical, inhalation, oral, IV, transmucosal) and dosage forms.


Services

Feasibility and API compatibility studies

Evaluate whether a partner's API is compatible with the nanoparticle platform and determine optimal product profiles in a cost-efficient and timely manner.

Partnerships and licensing with end-to-end project involvement

Collaborative development services from concept through product introduction including formulation development, preclinical testing support and commercialization planning.

Expertise Areas

  • Nanoparticle drug delivery
  • Topical and transdermal therapeutics
  • Inhalation/aerosol drug delivery
  • Wound healing therapeutics
  • Show More (5)

Key Technologies

  • Nitric oxide-releasing nanoparticles
  • Sol-gel / hydrogel-glass composite formulations
  • Nanoencapsulation for small molecules, peptides and antibodies
  • Aerosolization into nanoscale droplets (inhaler delivery)
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.